XPG Antibody (3C189): sc-73274
- XPG Antibody (3C189) is a mouse monoclonal IgG2a κ provided at 200 µg/ml
- raised against recombinant xeroderma pigmentosum group G of human origin
- recommended for detection of XPG of human origin by WB, IP, IF and FCM
- See XPG (8H7): sc-13563 for XPG antibody conjugates, including AC, HRP, FITC, PE, Alexa Fluor® 488, 594, 647, 680 and 790.
- m-IgG Fc BP-HRP and m-IgG2a BP-HRP are the preferred secondary detection reagents for XPG Antibody (3C189) for WB applications. These reagents are now offered in bundles with XPG Antibody (3C189) (see ordering information below).
QUICK LINKS
SEE ALSO...
XPG Antibody (3C189) is a mouse monoclonal IgG2a light chain antibody that detects XPG in human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and flow cytometry (FCM). XPG, also known as ERCC5, plays a crucial role in the nucleotide excision repair pathway, which is essential for maintaining genomic stability by repairing DNA lesions caused by ultraviolet radiation and various chemical agents. XPG functions as an endonuclease, specifically making the 3′ incision during the repair process, and XPG activity is vital for the proper excision of damaged DNA segments. The structural integrity of XPG is underscored by conserved residues within its catalytic center, which are critical for nuclease activity. Mutations or deficiencies in XPG can lead to xeroderma pigmentosum, a condition characterized by extreme sensitivity to UV light and a significantly increased risk of skin cancer. Anti-XPG antibody (3C189) serves as an invaluable tool for researchers studying DNA repair mechanisms and the implications of XPG in cancer biology.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
XPG Antibody (3C189) References:
- Hot topics in DNA repair: the molecular basis for different disease states caused by mutations in TFIIH and XPG. | Schärer, OD. 2008. DNA Repair (Amst). 7: 339-44. PMID: 18077223
- Quantitative assessment of the association between XPG Asp1104His polymorphism and bladder cancer risk. | Liu, C., et al. 2014. Tumour Biol. 35: 1203-9. PMID: 24061640
- Cdt2-mediated XPG degradation promotes gap-filling DNA synthesis in nucleotide excision repair. | Han, C., et al. 2015. Cell Cycle. 14: 1103-15. PMID: 25483071
- Regulation of Transcription Elongation by the XPG-TFIIH Complex Is Implicated in Cockayne Syndrome. | Narita, T., et al. 2015. Mol Cell Biol. 35: 3178-88. PMID: 26149386
- Non-catalytic Roles for XPG with BRCA1 and BRCA2 in Homologous Recombination and Genome Stability. | Trego, KS., et al. 2016. Mol Cell. 61: 535-546. PMID: 26833090
- XPG gene polymorphisms and cancer susceptibility: evidence from 47 studies. | Huang, J., et al. 2017. Oncotarget. 8: 37263-37277. PMID: 28416771
- The association between XPG polymorphisms and cancer susceptibility: Evidence from observational studies. | Han, C., et al. 2017. Medicine (Baltimore). 96: e7467. PMID: 28796034
- XPG-related nucleases are hierarchically recruited for double-stranded rDNA break resection. | Barnum, KJ., et al. 2019. J Biol Chem. 294: 7632-7643. PMID: 30885940
- Human XPG nuclease structure, assembly, and activities with insights for neurodegeneration and cancer from pathogenic mutations. | Tsutakawa, SE., et al. 2020. Proc Natl Acad Sci U S A. 117: 14127-14138. PMID: 32522879
- XPG gene polymorphisms and glioma susceptibility: a two-centre case-control study. | Yuan, L., et al. 2021. Br J Biomed Sci. 78: 135-140. PMID: 33393424
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
XPG Antibody (3C189) | sc-73274 | 200 µg/ml | $322.00 | |||
XPG Antibody (3C189): m-IgG Fc BP-HRP Bundle | sc-539468 | 200 µg Ab; 10 µg BP | $361.00 | |||
XPG Antibody (3C189): m-IgG2a BP-HRP Bundle | sc-546712 | 200 µg Ab; 10 µg BP | $361.00 |